Tag: Piramal Pharma Limited

Piramal Critical Care appoints Jeffrey Hampton as President & COO

Piramal Pharma Limited’s Piramal Critical Care (PCC) business, a producer of Inhaled Anesthetics and a global player in hospital generics, announced the appointment of Jeffrey Hampton as President & Chief Operating Officer (COO). For his new role, Hampton will be based in the United States. A Bachelor of Science in Marketing from University of Florida,…

Piramal Pharma appoints Vibha Paul Rishi as Non- Executive Director

Piramal Pharma Limited (PPL) announced the appointment of Vibha Paul Rishi to its Board of Directors. Rishi’s appointment will add to the well-diversified experience that currently exists across the PPL Board, a statement said. Rishi is a marketing professional and has held global leadership positions across branding, strategy, innovation and human capital. In the domains of marketing…

Piramal Pharma Ltd appoints Nathalie Leitch, Sridhar Gorthi and Peter Stevenson to its Board

Piramal Pharma Ltd (PPL) announced the addition of three members to its board of directors.  “We are pleased to welcome Mr. Peter Stevenson, Ms. Nathalie Leitch and Mr. Sridhar Gorthi to the board. These new appointments, which come ahead of the planned de-merger of PPL from Piramal Enterprises Ltd (PEL), will assist us in maintaining high governance for the new listed corporate entity,”…

Piramal Pharma to acquire 100% stake in Hemmo Pharmaceuticals

Piramal Pharma Limited’s (PPL) Contract Development and Manufacturing Organization (CDMO), Piramal Pharma Solutions (PPS), announced that PPL has entered into an agreement to acquire a 100% stake in Hemmo Pharmaceuticals Pvt Ltd. (Hemmo) for an upfront consideration of INR 775 crores and earn-outs linked to achievement of milestones. As PPS continues to expand and grow…

Piramal Pharma completes 20% strategic growth investment by Carlyle

Piramal Pharma Limited (PPL), a subsidiary of Piramal Enterprises Limited (PEL), announced that it has received INR 3523.40 Crores on closure of the transaction for 20% equity investment from CA Alchemy Investments (formerly known as CA Clover Intermediate II Investments), an affiliated entity of CAP V Mauritius Limited, an investment fund managed and advised by…